Richard W Tothill
Overview
Explore the profile of Richard W Tothill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
3815
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ugalde A, Tothill R, Quinn S, Wong H, Prall O, Mitchell C, et al.
BMC Cancer
. 2025 Jan;
25(1):171.
PMID: 39881222
Background: People with malignancy of undefined primary origin (MUO) have a poor prognosis and may undergo a protracted diagnostic workup causing patient distress and high cancer related costs. Not having...
2.
Hollizeck S, Wang N, Wong S, Litchfield C, Guinto J, Ftouni S, et al.
Nat Commun
. 2024 Nov;
15(1):9876.
PMID: 39543119
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational...
3.
Boehm E, Gill A, Clifton-Bligh R, Tothill R
Best Pract Res Clin Endocrinol Metab
. 2024 Sep;
38(6):101939.
PMID: 39271378
Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular...
4.
Sivakumaran T, Cardin A, Callahan J, Wong H, Tothill R, Hicks R, et al.
J Nucl Med
. 2024 Sep;
65(10):1557-1563.
PMID: 39237349
Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors for which standardized diagnostic work-up fails to identify the primary site. We aimed to describe the Peter MacCallum...
5.
Sivakumaran T, Tothill R, Mileshkin L
Curr Opin Oncol
. 2024 Jul;
36(5):456-464.
PMID: 39007224
Purpose Of Review: There is significant need to improve diagnostic and therapeutic options for patients with cancer of unknown primary (CUP). In this review, we discuss the evolving landscape of...
6.
Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, Dwight T, et al.
Res Sq
. 2024 Jul;
PMID: 38978571
Hereditary -mutant pheochromocytomas (PC) and paragangliomas (PG) are rare tumours with a high propensity to metastasize although their clinical behaviour is unpredictable. To characterize the genomic landscape of these tumours...
7.
Waldeck K, Van Zuylekom J, Cullinane C, Gulati T, Simpson K, Tothill R, et al.
Theranostics
. 2023 Sep;
13(14):4745-4761.
PMID: 37771787
Peptide receptor radionuclide therapy (PRRT) using Lutetium-DOTA-octreotate (LuTate) for neuroendocrine tumours (NET) is now an approved treatment available in many countries, though primary or secondary resistance continue to limit its...
8.
van Mourik A, Tonkin-Hill G, OFarrell J, Waller S, Tan L, Tothill R, et al.
Br J Cancer
. 2023 May;
129(2):301-308.
PMID: 37225894
Background: Diagnosis and management of cancers of unknown primary (CUP) remain challenging. This study examines the referral patterns, management and outcomes of patients referred to Australia's first dedicated CUP clinic....
9.
Kong G, Boehm E, Prall O, Murray W, Tothill R, Michael M
Curr Oncol Rep
. 2023 Feb;
25(5):465-478.
PMID: 36826704
Purpose Of Review: Gastroenteropancreatic NEN (GEP-NEN) are group of malignancies with significant clinical, anatomical and molecular heterogeneity. High-grade GEP-NEN in particular present unique management challenges. Recent Findings: In the current...
10.
Wolyniec K, OCallaghan C, Fisher K, Jessica S, Tothill R, Bowtell D, et al.
Psychooncology
. 2023 Jan;
32(4):589-596.
PMID: 36690922
Objective: Patients with Cancer of Unknown Primary (CUP) commonly report poor understanding of their illness and high levels of psychological distress. Despite the potential benefits to CUP patients, there is...